About Stoke Therapeutics
Stoke Therapeutics is a company based in Bedford (United States) founded in 2014 by Adrian Krainer. Stoke Therapeutics has raised $130.85 million across 3 funding rounds from investors including RTW Investments, RA Capital and Perceptive Advisors. The company has 128 employees as of December 31, 2024. Stoke Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Bedford, United States
- Employees 128 as on 31 Dec, 2024
- Founders Adrian Krainer
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stoke Therapeutics, Inc.
-
Annual Revenue
$36.55 M (USD)316.34as on Dec 31, 2024
-
Net Profit
-$88.98 M (USD)15.01as on Dec 31, 2024
-
EBITDA
-$96.93 M (USD)11.92as on Dec 31, 2024
-
Total Equity Funding
$130.85 M (USD)
in 3 rounds
-
Latest Funding Round
$90 M (USD), Series B
Oct 23, 2018
-
Investors
RTW Investments
& 6 more
-
Employee Count
128
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Stoke Therapeutics
Stoke Therapeutics is a publicly listed company on the NASDAQ with ticker symbol STOK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Stoke Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
18 people
Legal and Compliance
5 people
Human Resources and Administration
4 people
Clinical Team
3 people
Software Development Team
3 people
Finance and Accounting
2 people
Product Management Team
2 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Stoke Therapeutics
Stoke Therapeutics has successfully raised a total of $130.85M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $90 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stoke Therapeutics
Stoke Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include RTW Investments, RA Capital and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Stoke Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stoke Therapeutics
Investment portfolio details for Stoke Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Stoke Therapeutics
Detailed financials for Stoke Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stoke Therapeutics Comparisons
Peer comparison for Stoke Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stoke Therapeutics
Stoke Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Stoke Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stoke Therapeutics
Complete news archive for Stoke Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stoke Therapeutics
Stoke Therapeutics was founded in 2014.
Stoke Therapeutics is headquartered in Bedford, United States.
Edward M Kaye is the current CEO of Stoke Therapeutics.
Stoke Therapeutics is a funded company, having raised a total of $130.85M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Stoke Therapeutics is 128.
Annual revenue of Stoke Therapeutics is $36.55M as on Dec 31, 2024.
Stoke Therapeutics was founded in 2014 and is headquartered in Bedford, United States. Antisense oligonucleotide therapeutics are developed by the company to address inherited diseases through modulation of RNA splicing. The proprietary Targeted Augmentation of Nuclear Gene Output platform is utilized to enhance gene expression in a precise manner. A pipeline of candidates is being advanced for conditions affecting the central nervous system, eye, liver, and blood disorders.
Stoke Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Yes, Stoke Therapeutics is publicly traded on NASDAQ under the ticker symbol STOK.
Stoke Therapeutics has 7 investors. Key investors include RTW Investments, RA Capital, Perceptive Advisors, Apple Tree Partners, and Acks.
The ticker symbol of Stoke Therapeutics is STOK on NASDAQ.